抑制USP1通过去稳定MAX逆转复发/难治性B细胞淋巴瘤的化疗耐药
复发/难治性弥漫大B细胞淋巴瘤(DLBCL)预后差,亟需新策略。本研究发现USP1在DLBCL患者中高表达且高表达预示不良预后;敲低USP1或其特异性抑制剂匹莫齐特可抑制DLBCL细胞生长、诱导细胞周期阻滞和自噬;靶向USP1可减轻利妥昔单抗/化疗耐药DLBCL细胞小鼠模型的肿瘤负荷;匹莫齐特在DLBCL患者来源异种移植(PDX)模型中显著延缓淋巴瘤生长;USP1直接与MAX相互作用并通过去泛素化维持MAX稳定性,促进MYC靶基因转录;匹莫齐特与依托泊苷在耐药DLBCL细胞和小鼠模型中显示协同效应。
要点
- USP1在DLBCL患者中高表达,高表达预示不良预后。
- 敲低USP1或匹莫齐特抑制DLBCL细胞生长、诱导细胞周期阻滞和自噬。
- 匹莫齐特与依托泊苷在利妥昔单抗/化疗耐药DLBCL细胞和小鼠模型中显示协同效应。
核心结论
- USP1通过去泛素化MAX在DLBCL的利妥昔单抗/化疗耐药中起关键作用,为耐药DLBCL提供了新的治疗策略。
研究设计与样本
- 研究采用DLBCL患者样本、DLBCL细胞系、利妥昔单抗/化疗耐药DLBCL细胞小鼠模型和DLBCL患者来源异种移植(PDX)模型。
主要发现
- USP1在DLBCL患者中高表达,高表达预示不良预后。
- 敲低USP1或匹莫齐特诱导DLBCL细胞生长抑制、细胞周期阻滞和自噬。
- shRNA或匹莫齐特靶向USP1显著减轻利妥昔单抗/化疗耐药DLBCL细胞小鼠模型的肿瘤负荷。
- 匹莫齐特在DLBCL PDX模型中显著延缓淋巴瘤生长。
- USP1直接与MAX相互作用并通过去泛素化维持MAX稳定性,促进MYC靶基因转录。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) have poor prognosis, and a novel and effective therapeutic strategy for these patients is urgently needed. Although ubiquitin-specific protease 1 (USP1) plays a key role in cancer, the carcinogenic effect of USP1 in B-cell lymphoma remains elusive. Here we found that USP1 is highly expressed in DLBCL patients, and high expression of USP1 predicts poor prognosis. Knocking down USP1 or a specific inhibitor of USP1, pimozide, induced cell growth inhibition, cell cycle arrest and autophagy in DLBCL cells. Targeting USP1 by shRNA or pimozide significantly reduced tumor burden of a mouse model established with engraftment of rituximab/chemotherapy resistant DLBCL cells. Pimozide significantly retarded the growth of lymphoma in a DLBCL patient-derived xenograft (PDX) model. USP1 directly interacted with MAX, a MYC binding protein, and maintained the stability of MAX through deubiquitination, which promoted the transcription of MYC target genes. Moreover, pimozide showed a synergetic effect with etoposide, a chemotherapy drug, in cell and mouse models of rituximab/chemotherapy resistant DLBCL. Our study highlights the critical role of USP1 in the rituximab/chemotherapy resistance of DLBCL through deubiquitylating MAX, and provides a novel therapeutic strategy for rituximab/chemotherapy resistant DLBCL.
引用
- Li XY, Wu JC, Liu P, et al. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. Leukemia. 2022. PMID: 36352191. doi:10.1038/s41375-022-01747-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。